Small Molecules Targeting Protein-protein Interactions for Cancer Therapy

Overview

Journal Acta Pharm Sin B

Publisher Elsevier

Specialty Pharmacology

Date 2023 Oct 6

PMID 37799384

Authors

Defa Wu

Yang Li

Lang Zheng

Huan Xiao

Liang Ouyang

Guan Wang

Qiu Sun

Affiliations

Soon will be listed here.

Abstract

Protein-protein interactions (PPIs) are fundamental to many biological processes that play an important role in the occurrence and development of a variety of diseases. Targeting the interaction between tumour-related proteins with emerging small molecule drugs has become an attractive approach for treatment of human diseases, especially tumours. Encouragingly, selective PPI-based therapeutic agents have been rapidly advancing over the past decade, providing promising perspectives for novel therapies for patients with cancer. In this review we comprehensively clarify the discovery and development of small molecule modulators of PPIs from multiple aspects, focusing on PPIs in disease, drug design and discovery strategies, structure-activity relationships, inherent dilemmas, and future directions.

Citing Articles

Salicylaldehyde Benzoylhydrazones with Anticancer Activity and Selectivity: Design, Synthesis, and In Vitro Evaluation.

Nikolova-Mladenova B, Mihaylova R, Atanasova M, Zhivkova Z, Doytchinova I Molecules. 2025; 30(5).

PMID: 40076242 PMC: 11901818. DOI: 10.3390/molecules30051015.

DeepTGIN: a novel hybrid multimodal approach using transformers and graph isomorphism networks for protein-ligand binding affinity prediction.

Wang G, Zhang H, Shao M, Feng Y, Cao C, Hu X J Cheminform. 2024; 16(1):147.

PMID: 39734235 PMC: 11684089. DOI: 10.1186/s13321-024-00938-6.

Beyond ribosomal function: RPS6 deficiency suppresses cholangiocarcinoma cell growth by disrupting alternative splicing.

Fu W, Lin Y, Bai M, Yao J, Huang C, Gao L Acta Pharm Sin B. 2024; 14(9):3931-3948.

PMID: 39309509 PMC: 11413689. DOI: 10.1016/j.apsb.2024.06.028.

Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies.

Zhang J, Zhang Y, Wang J, Xia Y, Zhang J, Chen L Signal Transduct Target Ther. 2024; 9(1):211.

PMID: 39174535 PMC: 11344989. DOI: 10.1038/s41392-024-01911-3.

MGPPI: multiscale graph neural networks for explainable protein-protein interaction prediction.

Zhao S, Cui Z, Zhang G, Gong Y, Su L Front Genet. 2024; 15:1440448.

PMID: 39076171 PMC: 11284081. DOI: 10.3389/fgene.2024.1440448.

References

Kang M, Wan Z, Kang Y, Sposto R, Reynolds C . Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. J Natl Cancer Inst. 2008; 100(8):580-95. DOI: 10.1093/jnci/djn076. View

Zhao Y, Aguilar A, Bernard D, Wang S . Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment. J Med Chem. 2014; 58(3):1038-52. PMC: 4329994. DOI: 10.1021/jm501092z. View

Pan R, Hogdal L, Benito J, Bucci D, Han L, Borthakur G . Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2013; 4(3):362-75. PMC: 3975047. DOI: 10.1158/2159-8290.CD-13-0609. View

Yun C, Kim H, Lim J, Lee S . Heat Shock Proteins: Agents of Cancer Development and Therapeutic Targets in Anti-Cancer Therapy. Cells. 2019; 9(1). PMC: 7017199. DOI: 10.3390/cells9010060. View

Ward G, Lewis E, Ahn J, Johnson C, Lyons J, Martins V . ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth. Mol Cancer Ther. 2018; 17(7):1381-1391. DOI: 10.1158/1535-7163.MCT-17-0848. View

Gyrd-Hansen M, Meier P . IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer. 2010; 10(8):561-74. DOI: 10.1038/nrc2889. View

Parrales A, Iwakuma T . Targeting Oncogenic Mutant p53 for Cancer Therapy. Front Oncol. 2016; 5:288. PMC: 4685147. DOI: 10.3389/fonc.2015.00288. View

Wang L, Zhang Q, You Q . Targeting the HSP90-CDC37-kinase chaperone cycle: A promising therapeutic strategy for cancer. Med Res Rev. 2021; 42(1):156-182. DOI: 10.1002/med.21807. View

Hernandez Borrero L, El-Deiry W . Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta Rev Cancer. 2021; 1876(1):188556. PMC: 8730328. DOI: 10.1016/j.bbcan.2021.188556. View

10.

Oltersdorf T, Elmore S, Shoemaker A, Armstrong R, Augeri D, Belli B . An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005; 435(7042):677-81. DOI: 10.1038/nature03579. View

11.

Juric V, Hudson L, Fay J, Richards C, Jahns H, Verreault M . Transcriptional CDK inhibitors, CYC065 and THZ1 promote Bim-dependent apoptosis in primary and recurrent GBM through cell cycle arrest and Mcl-1 downregulation. Cell Death Dis. 2021; 12(8):763. PMC: 8333061. DOI: 10.1038/s41419-021-04050-7. View

12.

Chen H, Liu H, Qing G . Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct Target Ther. 2018; 3:5. PMC: 5837124. DOI: 10.1038/s41392-018-0008-7. View

13.

Biebl M, Buchner J . Structure, Function, and Regulation of the Hsp90 Machinery. Cold Spring Harb Perspect Biol. 2019; 11(9). PMC: 6719599. DOI: 10.1101/cshperspect.a034017. View

14.

Bier D, Rose R, Bravo-Rodriguez K, Bartel M, Ramirez-Anguita J, Dutt S . Molecular tweezers modulate 14-3-3 protein-protein interactions. Nat Chem. 2013; 5(3):234-9. DOI: 10.1038/nchem.1570. View

15.

Masso-Valles D, Soucek L . Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc. Cells. 2020; 9(4). PMC: 7226798. DOI: 10.3390/cells9040883. View

16.

Ramharter J, Kessler D, Ettmayer P, Hofmann M, Gerstberger T, Gmachl M . One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS. J Med Chem. 2021; 64(10):6569-6580. DOI: 10.1021/acs.jmedchem.0c01949. View

17.

Lu M, Ji J, Jiang Z, You Q . The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update. Med Res Rev. 2016; 36(5):924-63. DOI: 10.1002/med.21396. View

18.

Yee-Lin V, Pooi-Fong W, Soo-Beng A . Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment. Mini Rev Med Chem. 2017; 18(2):173-183. PMC: 5769085. DOI: 10.2174/1389557517666170717125821. View

19.

Kruiswijk F, Labuschagne C, Vousden K . p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nat Rev Mol Cell Biol. 2015; 16(7):393-405. DOI: 10.1038/nrm4007. View

20.

Yamamoto M, Kensler T, Motohashi H . The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis. Physiol Rev. 2018; 98(3):1169-1203. PMC: 9762786. DOI: 10.1152/physrev.00023.2017. View